ANKE BIO: The "AK2017 Injection" is expected to initiate Phase III clinical trials in early next yearZhitong·Oct 29, 2025 at 02:28 AM300009+0.36%
ANKE BIO released its performance for the first three quarters, with a net profit attributable to the parent company of 551 million yuan, a decrease of 6.48%Zhitong·Oct 27, 2025 at 10:33 AM300009+0.36%
ANKE BIO simultaneously launches Phase III clinical trials for two new drugs for pediatric respiratory viral infectionsZhitong·Oct 26, 2025 at 07:16 PM300009+0.36%
ANKE BIO: Innovative drug HuA21 injection will announce clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meetingZhitong·Oct 20, 2025 at 07:01 PM300009+0.36%
ANKE BIO: The ORR of HuA21 injection combined with trastuzumab and chemotherapy for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma reached 80.8%Zhitong·Oct 20, 2025 at 06:50 PM300009+0.36%
ANKE BIO: The company's controlling shareholder does not lend the shares held to quantitative institutions36Kr·Sep 28, 2025 at 12:01 AM300009+0.36%
ANKE BIO: The invested company PA3-17 injection has been approved to enter the critical Phase II clinical trialZhitong·Sep 17, 2025 at 05:48 AM300009+0.36%
ANKE BIO: Executives plan to reduce holdings by 1 million sharesZhitong·Sep 4, 2025 at 08:59 AM300009+0.36%
ANKE BIO: Exclusive agent product recombinant follicle-stimulating hormone-CTP fusion protein injection approved for market launchZhitong·Aug 25, 2025 at 05:45 AM300009+0.36%
ANKE BIO: Net profit in the first half of 2025 is 367 million yuan, a year-on-year decrease of 11.92%Zhitong·Aug 21, 2025 at 05:55 AM300009+0.36%
ANKE BIO: PA3-17 injection is included in the proposed breakthrough therapy categoryZhitong·Aug 8, 2025 at 04:01 AM300009+0.36%
Under the concept of innovative drugs, SDKX fell by more than 9%Zhitong·Aug 3, 2025 at 08:53 PM688136+3.63%688799+3.19%
ANKE BIO signed a strategic cooperation framework agreement with Weisheng PharmaceuticalZhitong·Jul 14, 2025 at 04:33 AM300009+0.36%
ANKE BIO establishes a new company, including remote health management services businessZhitong·Jul 3, 2025 at 09:40 PM300009+0.36%
